These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 8613969

  • 21. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
    Tapparelli C, Metternich R, Gfeller P, Gafner B, Powling M.
    Thromb Haemost; 1995 Apr; 73(4):641-7. PubMed ID: 7495072
    [Abstract] [Full Text] [Related]

  • 22. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

  • 23. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 04; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 24. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
    Zafar MU, Farkouh ME, Osende J, Shimbo D, Palencia S, Crook J, Leadley R, Fuster V, Chesebro JH.
    Thromb Haemost; 2007 Mar 04; 97(3):487-92. PubMed ID: 17334518
    [Abstract] [Full Text] [Related]

  • 25. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA, Steinbacher TE, Heran CL, Seiler SM, Michel IM, Ogletree ML.
    J Pharmacol Exp Ther; 1993 Dec 04; 267(3):1237-42. PubMed ID: 8263785
    [Abstract] [Full Text] [Related]

  • 26. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K, Hornberger W.
    Thromb Haemost; 1996 Jul 04; 76(1):105-10. PubMed ID: 8819261
    [Abstract] [Full Text] [Related]

  • 27. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY, Pinto DJ, Wexler RR, Knabb RM.
    J Pharmacol Exp Ther; 2002 Dec 04; 303(3):993-1000. PubMed ID: 12438519
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA, Abrahamsson TI, Nerme VK, Mattsson CJ.
    Thromb Res; 2005 Dec 04; 116(6):519-24. PubMed ID: 16181987
    [Abstract] [Full Text] [Related]

  • 29. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y.
    Thromb Haemost; 1995 Nov 04; 74(5):1286-92. PubMed ID: 8607111
    [Abstract] [Full Text] [Related]

  • 30. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
    Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y.
    Thromb Haemost; 1998 Jan 04; 79(1):162-8. PubMed ID: 9459343
    [Abstract] [Full Text] [Related]

  • 31. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Fiedler VB, Perzborn E, Seuter F, Rosentreter U, Böshagen H.
    Arzneimittelforschung; 1989 Dec 04; 39(12):1527-30. PubMed ID: 2624600
    [Abstract] [Full Text] [Related]

  • 32. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
    Mattsson C, Björkman JA, Abrahamsson T, Nerme V, Schatteman K, Leurs J, Scharpé S, Hendriks D.
    Thromb Haemost; 2002 Apr 04; 87(4):557-62. PubMed ID: 12008935
    [Abstract] [Full Text] [Related]

  • 33. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
    Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TG.
    J Cardiovasc Pharmacol; 1998 Mar 04; 31(3):345-51. PubMed ID: 9514177
    [Abstract] [Full Text] [Related]

  • 34. Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus.
    Shebuski RJ, Ramjit DR, Sitko GR, Lumma PK, Garsky VM.
    Thromb Haemost; 1990 Dec 28; 64(4):576-81. PubMed ID: 2084943
    [Abstract] [Full Text] [Related]

  • 35. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
    Wong PC, Crain EJ, Knabb RM, Meade RP, Quan ML, Watson CA, Wexler RR, Wright MR, Slee AM.
    J Pharmacol Exp Ther; 2000 Oct 28; 295(1):212-8. PubMed ID: 10991981
    [Abstract] [Full Text] [Related]

  • 36. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
    Chesebro JH, Webster MW, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ.
    Circulation; 1992 Dec 28; 86(6 Suppl):III100-10. PubMed ID: 1424043
    [Abstract] [Full Text] [Related]

  • 37. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
    Heran C, Morgan S, Kasiewski C, Bostwick J, Bentley R, Klein S, Chu V, Brown K, Colussi D, Czekaj M, Perrone M, Leadley R.
    Eur J Pharmacol; 2000 Feb 18; 389(2-3):201-7. PubMed ID: 10688985
    [Abstract] [Full Text] [Related]

  • 38. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS, Bentley RG, Morgan SR, Kasiewski CJ, Chu V, Perrone MH, Leadley RJ.
    Br J Pharmacol; 2001 Aug 18; 133(7):1190-8. PubMed ID: 11487531
    [Abstract] [Full Text] [Related]

  • 39. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
    Imura Y, Stassen JM, Collen D.
    J Pharmacol Exp Ther; 1992 Jun 18; 261(3):895-8. PubMed ID: 1602394
    [Abstract] [Full Text] [Related]

  • 40. Experimental carotid thrombosis in the guinea pig.
    Roux S, Carteaux JP, Hess P, Falivene L, Clozel JP.
    Thromb Haemost; 1994 Feb 18; 71(2):252-6. PubMed ID: 8191408
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.